Carisma Therapeutics (NASDAQ:CARM) Insider Sells $42,900.00 in Stock

Carisma Therapeutics Inc. (NASDAQ:CARM) insider Michael Klichinsky sold 165,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $0.26, for a total transaction of $42,900.00. Following the completion of the transaction, the insider directly owned 319,347 shares of the company’s stock, valued at $83,030.22. The trade was a 34.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Klichinsky also recently made the following trade(s):

• On Friday, October 3rd, Michael Klichinsky sold 119,347 shares of Carisma Therapeutics stock. The stock was sold at an average price of $0.26, for a total transaction of $31,030.22.
• On Thursday, October 2nd, Michael Klichinsky sold 200,000 shares of Carisma Therapeutics stock. The stock was sold at an average price of $0.25, for a total transaction of $50,000.00.

Carisma Therapeutics Price Performance

Shares of CARM opened at $0.26 on Monday. The company’s fifty day moving average price is $0.30 and its 200-day moving average price is $0.30. Carisma Therapeutics Inc. has a 1-year low of $0.14 and a 1-year high of $1.27. The firm has a market capitalization of $10.90 million, a PE ratio of -0.17 and a beta of 2.06.

Analysts Set New Price Targets

Several analysts have recently commented on CARM shares. Evercore ISI raised shares of Carisma Therapeutics to a “strong-buy” rating in a report on Tuesday, July 15th. D. Boral Capital reaffirmed a “buy” rating and issued a $1.00 price target on shares of Carisma Therapeutics in a report on Friday, August 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Carisma Therapeutics in a research note on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Carisma Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $1.93.

Institutional Investors Weigh In On Carisma Therapeutics

An institutional investor recently bought a new position in Carisma Therapeutics stock. Jane Street Group LLC purchased a new stake in Carisma Therapeutics Inc. (NASDAQ:CARM) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 0.36% of Carisma Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.